FindTrial
Sign In

Effects of Suvorexant on sleep disorder and BPSD(Behavioral and Psychological Symptoms of Dementia) of Alzheimer's disease

Effects of Suvorexant on sleep disorder and BPSD(Behavioral and Psychological Symptoms of Dementia) of Alzheimer's disease - Effects of Suvorexant on sleep disorder and BPSD(Behavioral and Psychological Symptoms of Dementia) of Alzheimer's disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000018127
Enrollment
40
Registered
2015-06-30
Start date
2015-06-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer&#39

Interventions

Suvorexant 15mg/day for 4weeks Ramelteon 8mg/day for 4weeks

Sponsors

Department of Psychiatry, Jikei university school of medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The Patient of Alzheimer's disease, it was judged the medical attendant to have the insomnia that treatment needed.

Exclusion criteria

Exclusion criteria: Patient with a history of the mental disorder, Patient with a history of the contusion of head, Patient with a history of the harmful use of Alcohol or drugs, Severe Alzheimer's disease, Patient who use psychotropic drugs, Resident of a nursing home, Patient who does not have a reliable caregiver

Design outcomes

Primary

MeasureTime frame
Actigraph, MMSE(Mini Mental State Examination), NPI(Neuropsychiatric Inventory), ZBI(Zarit Burden Interview), DRS(Delirium Rating Scale), ESS(Epworth Sleepiness Scale), ISI(Insomnia Severity Index)—

Countries

Japan

Contacts

Public ContactRyo Aoki

Jikei university school of medicine Psychiatry

ryo-fcb@samba.ocn.ne.jp03-3433-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026